Aranidipine
Drug profile
Also known as: sapresta
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Aranidipine is a drug catalogued in DrugCentral. DrugCentral lists 1 molecular target, including CACNA1D|CACNA1C. Recorded indications include Hypertensive disorder.
- Molecular targets: CACNA1D|CACNA1C (1 listed in DrugCentral).
- Indications: Hypertensive disorder.
- Molecular formula: C19H20N2O7; molecular weight 388.38 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hypertensive disorder
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Voltage-gated L-type calcium channel | CACNA1D|CACNA1C | blocker | — |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Aranidipine is on its molecule page.
| Molecular formula | C19H20N2O7 |
|---|---|
| Molecular weight | 388.38 g/mol |
| CAS number | 86780-90-7 |
| InChIKey | NCUCGYYHUFIYNU-UHFFFAOYSA-N |
| PubChem CID | 2225 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Aranidipine used for?
DrugCentral lists the following indications for Aranidipine: Hypertensive disorder.
How does Aranidipine work?
Its molecular targets in DrugCentral include CACNA1D|CACNA1C (blocker).
What is the chemical formula of Aranidipine?
Aranidipine has the molecular formula C19H20N2O7 and a molecular weight of 388.38 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 234 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2104030 — compound record and bioactivity
- PubChem CID 2225 — chemical identifiers
- DrugBank DB09229 — drug record
- FDA UNII 4Y7UR6X2PO — substance identity
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.